pillbase.ru

Reblozyl

Active substance: luspatercept

Luspatercept

Centralised EU authorisationActive

Marketing holder: Bristol Myers Squibb Pharma EEIG

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 2
  • Reblozyl
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · LUSPATERCEPT 75 mg/1
    59572-775
    Celgene Corporation
  • Reblozyl
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · LUSPATERCEPT 25 mg/1
    59572-711
    Celgene Corporation
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208e-8a61-75b5-8718-91a42763270f,01a1209b-57fe-721f-8ac1-101c246f28df;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004444
Registration status
Active
ATC code
B03XA06
Sources
  • product · EMA · EMEA/H/C/004444 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004444 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004444 · Verified 2026-10-09